Linda A. Doody

Linda A. Doody, PhD, DABT, Executive Director, directs CCSA’s regulatory affairs and safety reporting activities in support of commercial, government, and nonprofit drug development. Dr. Doody has developed strategies, coordinated with pharmaceutical partners, served as liaison with FDA, and reviewed and prepared more than 3300 submissions to over 100 Investigational New Drug applications (INDs) and Clinical Trial Agreements. Dr. Doody was responsible for the development and implementation of the Master IND. She serves as a clinical safety expert for NIH and commercial studies and has managed processing and assessing over 1700 serious adverse event reports. Dr. Doody is certified as a Diplomate of the American Board of Toxicology (DABT) and holds a PhD in pharmacology and toxicology.